TCIM
SAGE

TIAA CREF Investment Management’s Sage Therapeutics SAGE Stock Holding History

TIAA CREF Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$61.2M Buy
384,925
+232,926
+153% +$33.7M 0.04% 357
2018
Q4 		$14.6M Sell
151,999
-17,706
-10% -$2.03M 0.01% 784
2018
Q3 		$24M Sell
169,705
-13,379
-7% -$2.07M 0.02% 665
2018
Q2 		$28.7M Sell
183,084
-47,511
-21% -$7.46M 0.02% 606
2018
Q1 		$37.1M Buy
230,595
+102,805
+80% +$17.5M 0.03% 529
2017
Q4 		$21M Buy
127,790
+7,276
+6% +$705K 0.01% 768
2017
Q3 		$7.51M Sell
120,514
-2,040
-2% -$160K 0.01% 1345
2017
Q2 		$9.76M Buy
122,554
+21,527
+21% +$1.56M 0.01% 1150
2017
Q1 		$7.18M Sell
101,027
-1,840
-2% -$108K 0.01% 1347
2016
Q4 		$5.25M Buy
102,867
+602
+0.6% +$28.4K ﹤0.01% 1565
2016
Q3 		$4.71M Buy
102,265
+13,744
+16% +$559K ﹤0.01% 1650
2016
Q2 		$2.67M Buy
88,521
+34,248
+63% +$1.14M ﹤0.01% 1951
2016
Q1 		$1.74M Buy
54,273
+3,227
+6% +$114K ﹤0.01% 2161
2015
Q4 		$2.98M Sell
51,046
-8,282
-14% -$410K ﹤0.01% 1908
2015
Q3 		$2.51M Buy
59,328
+14,783
+33% +$911K ﹤0.01% 2010
2015
Q2 		$3.25M Buy
44,545
+28,284
+174% +$1.82M ﹤0.01% 1983
2015
Q1 		$817K Buy
16,261
+1,865
+13% +$80.2K ﹤0.01% 2728
2014
Q4 		$527K Buy
14,396
+2,099
+17% +$78.2K ﹤0.01% 2947
2014
Q3 		$387K Buy
+12,297
New +$356K ﹤0.01% 3023

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TIAA CREF Investment Management's SAGE Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Sage Therapeutics (SAGE) stake by 153% in Q1 2019, buying an estimated $33.7M and bringing the position to 384,925 shares worth $61.2M. The position accounts for 0.04% of the portfolio, ranked #357.

TIAA CREF Investment Management first reported a position in SAGE in Q3 2014 and has held it in 19 quarters since. 268 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

  • TIAA CREF Investment Management held 384,925 shares of Sage Therapeutics worth $61.2M as of Q1 2019.
  • TIAA CREF Investment Management bought 232,926 Sage Therapeutics shares in Q1 2019, an estimated $33.7M.
  • Sage Therapeutics made up 0.04% of TIAA CREF Investment Management's portfolio in Q1 2019, its #357 holding.
  • TIAA CREF Investment Management first reported a position in Sage Therapeutics in Q3 2014 and has held it in 19 quarters since.
  • 268 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.